Triazole resistance is still not emerging in A fumigatus isolates causing invasive aspergillosis in Brazilian patients.

Triazole resistance is still not emerging in A fumigatus isolates causing invasive aspergillosis in Brazilian patients.
Antimicrob Agents Chemother. 2017 Sep 11;:
Authors: Negri CE, Gonçalves SS, Sousa ACP, Bergamasco MD, Martino MDV, Queiroz-Telles F, Aquino VR, Castro PTO, Hagen F, Meis JF, Colombo AL
Abstract
Aspergillus fumigatus azole resistance has globally emerged as a health problem. We evaluated the in vitro antifungal susceptibility of 221 clinical A. fumigatus isolates according to CLSI. Sixty-one isolates exhibiting MIC at the epidemiological cut-off value (ECV) for itraconazole or above ECV for any triazole were checked for CYP51A mutations. No mutations were documented, even for four isolates (1.8%) with high voriconazole MICs, indicating that triazoles may be safely used to treat aspergillosis in Brazil.
PMID: 28893772 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - September 11, 2017 Category: Microbiology Authors: Negri CE, Gonçalves SS, Sousa ACP, Bergamasco MD, Martino MDV, Queiroz-Telles F, Aquino VR, Castro PTO, Hagen F, Meis JF, Colombo AL Tags: Antimicrob Agents Chemother Source Type: research